Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics.
Ten human immunodeficiency virus-infected patients were given rifabutin in addition to fluconazole and clarithromycin. There was a 76% increase in the area under the concentration-time curve of rifabutin when either fluconazole or clarithromycin was given alone and a 152% increase when both drugs were given together with rifabutin. Patients should be monitored for adverse effects of rifabutin administered concomitantly with clarithromycin and/or fluconazole.
Jordan
M K
MK
Department of Pharmacy, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Polis
M A
MA
Kelly
G
G
Narang
P K
PK
Masur
H
H
Piscitelli
S C
SC
D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000904:Antibiotics, Antitubercular / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics; D000935:Antifungal Agents / Q000494:pharmacology; D017291:Clarithromycin / Q000494:pharmacology*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D015725:Fluconazole / Q000494:pharmacology*; D015658:HIV Infections / Q000097:blood / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017828:Rifabutin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics*
D000900:Anti-Bacterial Agents; D000904:Antibiotics, Antitubercular; D000935:Antifungal Agents; C107196:25-desacetylrifabutin; D017828:Rifabutin; D015725:Fluconazole; D017291:Clarithromycin